Active, not recruitingPHASE1, PHASE2NCT02911142

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Studying Primary effusion lymphoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Ramya Ramaswami, M.D., M.D
National Cancer Institute (NCI)
Intervention: Lenalidomide(drug)
Enrollment: 17 enrolled
Eligibility: 18 years · All sexes
Timeline: 2017 – 2027

Study locations (1)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02911142 on ClinicalTrials.gov

← Back to all trials